{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:24:59Z","timestamp":1786933499887,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019559","name":"Carl von Ossietzky Universit\u00e4t Oldenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019559","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Methotrexate (MTX) can induce adverse drug reactions (ADRs) including severe haematotoxic events. This study analyses whether agranulocytosis is disproportionately reported in spontaneous reports involving MTX for rheumatoid arthritis (RA) when use of metamizole, a non-opioid analgesic, which itself has been associated with agranulocytosis, is recorded additionally. Using the EudraVigilance database, we analyzed spontaneous reports of suspected ADRs associated with MTX for RA and including any comedication (from Europe, until 2022). We (i) compared characteristics of reports stratified by metamizole use and the occurrence of agranulocytosis and (ii) performed disproportionality analyses estimating reporting odds ratios (RORs) and 95% confidence intervals (CIs) of agranulocytosis associated with metamizole. We included 7,213 reports with recorded use of MTX for RA (72.1% female, median age: 64\u00a0years, 11.3% with an agranulocytosis, 1.7% with metamizole use). Compared to reports with other comedication, metamizole users were older and more often received also other analgesics such as opioids (27.3% vs. 8.9%) while treatment with additional disease-modifying anti-rheumatic drugs (DMARDs) was less common (34.7% vs. 62.2%). Agranulocytosis was disproportionately recorded in reports also involving metamizole (ROR: 9.8; 95% CI: 6.8\u201314.1). The ROR decreased after adjusting for age, sex, other analgesics and DMARDs (ROR: 5.5; 95% CI: 3.6\u20138.6). The highest ROR was found in individuals aged 80\u2009+\u2009. Our study supports regulatory warnings that a concurrent administration of metamizole can increase the haematotoxic effect of MTX and should therefore be avoided. A sufficient RA therapy might decrease the need for analgesics and should be aimed at also in older RA patients.<\/jats:p>","DOI":"10.1007\/s00210-026-05819-3","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:12:55Z","timestamp":1786932775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Agranulocytosis associated with metamizole among EudraVigilance reports involving methotrexate for rheumatoid arthritis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-9721","authenticated-orcid":false,"given":"Kathrin","family":"Jobski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-8081","authenticated-orcid":false,"given":"Carsten","family":"Bantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-0294","authenticated-orcid":false,"given":"Katinka","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0182-5373","authenticated-orcid":false,"given":"Falk","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"5819_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00393-021-00971-y","volume":"80","author":"K Albrecht","year":"2021","unstructured":"Albrecht K, Marschall U, Callhoff J (2021) Prescription of analgesics in patients with rheumatic diseases in Germany. Z Rheumatol 80:68-75. https:\/\/doi.org\/10.1007\/s00393-021-00971-y","journal-title":"Z Rheumatol"},{"key":"5819_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1055\/a-1672-2067","volume":"42","author":"K Albrecht","year":"2022","unstructured":"Albrecht K, Thiele K, Sp\u00e4thling S (2022) Therapiespektrum \u00e4lterer Menschen mit rheumatoider Arthritis. Arthritis Rheuma 42:8-14. https:\/\/doi.org\/10.1055\/a-1672-2067","journal-title":"Arthritis Rheuma"},{"key":"5819_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. https:\/\/doi.org\/10.1002\/pds.1742","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5819_CR4","doi-asserted-by":"publisher","DOI":"10.23937\/2469-5726\/1510070","author":"R Bergner","year":"2019","unstructured":"Bergner R, Wadsack D, L\u00f6ffler C (2019) Severe MTX toxicity in rheumatic diseases - analysis of 22 cases. J Rheum Dis Treat. https:\/\/doi.org\/10.23937\/2469-5726\/1510070","journal-title":"J Rheum Dis Treat"},{"key":"5819_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00228-014-1781-z","volume":"71","author":"LS Blaser","year":"2014","unstructured":"Blaser LS, Tramonti A, Egger P (2014) Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports. Eur J Clin Pharmacol 71:209 217.  https:\/\/doi.org\/10.1007\/s00228-014-1781-z","journal-title":"Eur J Clin Pharmacol"},{"key":"5819_CR6","doi-asserted-by":"publisher","first-page":"204209862412752","DOI":"10.1177\/20420986241275255","volume":"15","author":"B Br\u00fcne","year":"2024","unstructured":"Br\u00fcne B, Sonderer S, B\u00f6sing M (2024) Assessing potential risk factors for metamizole-induced leukopenia. Ther Adv Drug Saf 15:20420986241275256. https:\/\/doi.org\/10.1177\/20420986241275255","journal-title":"Ther Adv Drug Saf"},{"key":"5819_CR7","unstructured":"Chiravuri S, De Jesus O (2023) Pancytopenia. In: StatPearls Treasure Isl. StatPearls Publ. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563146\/"},{"key":"5819_CR8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1136\/annrheumdis-2011-200702","volume":"71","author":"WG Dixon","year":"2012","unstructured":"Dixon WG, Abrahamowicz M, Beauchamp M-E (2012) Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case\u2013control analysis. Ann Rheum Dis 71:1128-1133. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200702","journal-title":"Ann Rheum Dis"},{"key":"5819_CR9","unstructured":"European Medicines Agency (EMA) (2019a) Referral under Article 31 of Directive 2001\/83\/EC resulting from pharmacovigilance data Procedure number: EMEA\/H\/A-31\/1463. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/methotrexate-article-31-referral-public-assessment-report-emeaha-311463_en.pdf. Accessed 1 May 2025"},{"key":"5819_CR10","unstructured":"European Medicines Agency (EMA) (n.d.b) EudraVigilance. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance\/eudravigilance-system-overview. Accessed 5 Jan 2025"},{"key":"5819_CR11","unstructured":"European Medicines Agency (EMA) (2024) Assessment report Referral under Article 107i of Directive 2001\/83\/EC INN\/active substance: metamizole Procedure number: EMEA\/H\/A-107i\/1537. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/metamizole-containing-medicinal-products-article-107i-referral-assessment-report_en.pdf"},{"key":"5819_CR12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR (2021) 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 73:924-939.  https:\/\/doi.org\/10.1002\/acr.24596","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5819_CR13","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s40266-020-00801-x","volume":"37","author":"R Freitas","year":"2020","unstructured":"Freitas R, Godinho F, Madeira N (2020) Safety and effectiveness of biologic disease-modifying antirheumatic drugs in older patients with rheumatoid arthritis: a prospective cohort study. Drugs Aging 37:899-907. https:\/\/doi.org\/10.1007\/s40266-020-00801-x","journal-title":"Drugs Aging"},{"key":"5819_CR14","first-page":"1","volume-title":"Handbook of epidemiology","author":"E Garbe","year":"2022","unstructured":"Garbe E, Suissa S, Douros A (2022) Pharmacoepidemiology. Handbook of epidemiology. Springer, New York New York, NY, pp 1\u201355"},{"key":"5819_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3899\/jrheum.180178","volume":"46","author":"MD George","year":"2019","unstructured":"George MD, Sauer BC, Teng C-C (2019) Biologic and glucocorticoid use after methotrexate initiation in patients with rheumatoid arthritis. J Rheumatol 46:343-350.  https:\/\/doi.org\/10.3899\/jrheum.180178","journal-title":"J Rheumatol"},{"key":"5819_CR16","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12325-020-01522-8","volume":"38","author":"C Grellmann","year":"2021","unstructured":"Grellmann C, Dombrowsky W, Fabricius V (2021) Epidemiology and treatment of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis in Germany: a real-world evidence study. Adv Ther 38:366-385. https:\/\/doi.org\/10.1007\/s12325-020-01522-8","journal-title":"Adv Ther"},{"key":"5819_CR17","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0895-4356(02)00450-X","volume":"55","author":"J Hasford","year":"2002","unstructured":"Hasford J, Goettler M, Munter K-H, M\u00fcller-Oerlinghausen B (2002) Physicians\u2019 knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol 55:945-950","journal-title":"J Clin Epidemiol"},{"key":"5819_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bcpt.13310","volume":"126","author":"F Hoffmann","year":"2020","unstructured":"Hoffmann F, Bantel C, Jobski K (2020) Agranulocytosis attributed to metamizole: an analysis of spontaneous reports in EudraVigilance 1985\u20132017. Basic Clin Pharmacol Toxicol 126:116-125. https:\/\/doi.org\/10.1111\/bcpt.13310","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"5819_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17113892","volume":"17","author":"F Hoffmann","year":"2020","unstructured":"Hoffmann F, Bantel C, Rosen von FT, Jobski K (2020) Regional differences in prescribing patterns of metamizole in Germany based on data from 70 million persons. Int J Environ Res Public Health 17:3892. https:\/\/doi.org\/10.3390\/ijerph17113892","journal-title":"Int J Environ Res Public Health"},{"key":"5819_CR20","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40744-021-00344-6","volume":"8","author":"T Hunter","year":"2021","unstructured":"Hunter T, Nguyen C, Birt J (2021) Pain medication and corticosteroid use in ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis in the United States: a retrospective observational study. Rheumatol Ther 8:1371 1382. https:\/\/doi.org\/10.1007\/s40744-021-00344-6","journal-title":"Rheumatol Ther"},{"key":"5819_CR21","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human (2024a) Use (ICH) Introductory Guide MedDRA Version 27.1. https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_27_1_English.pdf. Accessed 1 May 2025"},{"key":"5819_CR22","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Introductory Guide for Standardised MedDRA Queries (SMQs) Version 27.1 (2024b)\u00a0https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/SMQ_intguide_27_1_English.pdf. Accessed 1 May 2025"},{"key":"5819_CR23","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/pds.4202","volume":"26","author":"K Jobski","year":"2017","unstructured":"Jobski K, Luque Ramos A, Albrecht K, Hoffmann F (2017) Pain, depressive symptoms and medication in German patients with rheumatoid arthritis-results from the linking patient-reported outcomes with claims data for health services research in rheumatology (PROCLAIR) study. Pharmacoepidemiol Drug Saf 26:766-774. https:\/\/doi.org\/10.1002\/pds.4202","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5819_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5865","volume":"33","author":"K Jobski","year":"2024","unstructured":"Jobski K, Ritschel M, P\u00f6ggel-Kr\u00e4mer K (2024) Pain medication and pain intensity following hip fractures-analyses based on the ProFem cohort study. Pharmacoepidemiol Drug Saf 33:e5865. https:\/\/doi.org\/10.1002\/pds.5865","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5819_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13075-025-03551-6","volume":"27","author":"K Khoroshun","year":"2025","unstructured":"Khoroshun K, Bantel C, Hoffmann F, Jobski K (2025) Methotrexate-related drug reactions on kidneys and liver in rheumatoid arthritis: an analysis of spontaneous reports in EudraVigilance. Arthritis Res Ther 27:80. https:\/\/doi.org\/10.1186\/s13075-025-03551-6","journal-title":"Arthritis Res Ther"},{"key":"5819_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003827","volume":"10","author":"C Kumar","year":"2024","unstructured":"Kumar C, Kuhn M, Herrmann K (2024) Severe methotrexate toxicity in elderly patients under diuretics. RMD Open 10:e003827. https:\/\/doi.org\/10.1136\/rmdopen-2023-003827","journal-title":"RMD Open"},{"key":"5819_CR27","unstructured":"medac (2024) metex\u00ae 7,5 mg\/10 mg Tabletten. https:\/\/www.medac.eu\/fileadmin\/user_upload\/medac-eu\/SPCs\/Germany\/spc-de-metex_7_5mg-10mg_Tabletten.pdf"},{"key":"5819_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154744","volume":"11","author":"S Mori","year":"2016","unstructured":"Mori S, Hidaka M, Kawakita T (2016) Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases. PLoS ONE 11:e0154744. https:\/\/doi.org\/10.1371\/journal.pone.0154744","journal-title":"PLoS ONE"},{"key":"5819_CR29","unstructured":"\u00a0Nordimet (2025)\u00a0Nordimet: EPAR - Product Information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nordimet-epar-product-information_en.pdf"},{"key":"5819_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1030832","author":"K Onda","year":"2023","unstructured":"Onda K, Honma T, Masuyama K (2023) Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: an assessment using the FDA adverse event reporting system. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1030832","journal-title":"Front Pharmacol"},{"key":"5819_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40801-024-00416-3","volume":"11","author":"SK Peasah","year":"2024","unstructured":"Peasah SK, Swart ECS, Huang Y (2024) Disease-modifying medications in patients with rheumatoid arthritis in the USA: trends from 2016 to 2021. Drugs Real World Outcomes 11:241-249. https:\/\/doi.org\/10.1007\/s40801-024-00416-3","journal-title":"Drugs Real World Outcomes"},{"key":"5819_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.727717","author":"B Rattay","year":"2021","unstructured":"Rattay B, Benndorf RA (2021) Drug-induced idiosyncratic agranulocytosis - infrequent but dangerous. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.727717","journal-title":"Front Pharmacol"},{"key":"5819_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","volume":"81","author":"I Redeker","year":"2022","unstructured":"Redeker I, Albrecht K, Kekow J (2022) Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis 81:41-47. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220651","journal-title":"Ann Rheum Dis"},{"key":"5819_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1194","author":"L Reist","year":"2018","unstructured":"Reist L, Erlenwein J, Meissner W (2018) Dipyrone is the preferred nonopioid analgesic for the treatment of acute and chronic pain. A survey of clinical practice in German-speaking countries. Eur J Pain. https:\/\/doi.org\/10.1002\/ejp.1194","journal-title":"Eur J Pain"},{"key":"5819_CR35","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/rheumatology\/kead463","volume":"63","author":"IC Scott","year":"2024","unstructured":"Scott IC, Whittle R, Bailey J (2024) Analgesic prescribing in patients with inflammatory arthritis in England: observational studies in the Clinical Practice Research Datalink. Rheumatology 63:1672-1681. https:\/\/doi.org\/10.1093\/rheumatology\/kead463","journal-title":"Rheumatology (Oxford)"},{"key":"5819_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102528","volume":"19","author":"L Serhal","year":"2020","unstructured":"Serhal L, Lwin MN, Holroyd C, Edwards CJ (2020) Rheumatoid arthritis in the elderly: characteristics and treatment considerations. Autoimmun Rev 19:102528. https:\/\/doi.org\/10.1016\/j.autrev.2020.102528","journal-title":"Autoimmun Rev"},{"key":"5819_CR37","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1093\/rheumatology\/keab304","volume":"60","author":"AA Sherbini","year":"2021","unstructured":"Sherbini AA, Sharma SD, Gwinnutt JM (2021) Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review. Rheumatology 60:4001-4017. https:\/\/doi.org\/10.1093\/rheumatology\/keab304","journal-title":"Rheumatology (Oxford)"},{"key":"5819_CR38","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964-975. https:\/\/doi.org\/10.1136\/ard.2009.126532","journal-title":"Ann Rheum Dis"},{"key":"5819_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:3-18. https:\/\/doi.org\/10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"key":"5819_CR40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M19-3369","volume":"172","author":"DH Solomon","year":"2020","unstructured":"Solomon DH, Glynn RJ, Karlson EW (2020) Adverse effects of low-dose methotrexate. Ann Intern Med 172:369-380. https:\/\/doi.org\/10.7326\/M19-3369","journal-title":"Ann Intern Med"},{"key":"5819_CR41","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s00228-015-1895-y","volume":"71","author":"T Stammschulte","year":"2015","unstructured":"Stammschulte T, Ludwig W-D, M\u00fchlbauer B (2015) Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990-2012. Eur J Clin Pharmacol 71:1129-1138. https:\/\/doi.org\/10.1007\/s00228-015-1895-y","journal-title":"Eur J Clin Pharmacol"},{"key":"5819_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002700","volume":"8","author":"L Tidblad","year":"2022","unstructured":"Tidblad L, Westerlind H, Delcoigne B (2022) Comorbidities and treatment patterns in early rheumatoid arthritis: a nationwide Swedish study. RMD Open 8:e002700. https:\/\/doi.org\/10.1136\/rmdopen-2022-002700","journal-title":"RMD Open"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05819-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05819-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05819-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:12:58Z","timestamp":1786932778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05819-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":42,"alternative-id":["5819"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05819-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}